Approximately one-fourth of the respondents have highlighted that reducing the focus on diabetes treatment (Q3.7, 22% - n = 17) and having less liability (Q3.8, 29% - n = 22) in insulin dosage calculation would be another significant advantage of using such medical devices. This evidence concerns the gene INS and diabetes mellitus.